Amarin Corp Plc (AMRN)

[hamkypamky]

They have Austedeo and Ajovy as well - which combined do nearly $1B of revenue.

Also do not be misled by REVENUE.

TEVA as a company doesn't need revenue - it needs MARGINS to pay for its interest expense (almost $1B annually) on $27B(!) of debt.

This is not a company that can aggressively push a low-margin generic drug. Not unless they refinance half of that $27B at 0.25% interest (and that is a longshot).

They would be more likely to buy AMRN outright and get Vascepa margins of 70% then go for generic vascepa, in what is likely to be a low-margin play (maybe 30-40% gross, at best) plus with significant SG&A expenses involved.